an overall weighted average for sensitivity and specificity was calculated using the weighted averages of the sample sizes in each relevant study. Pooled estimates of positive and negative likelihood ratios were calculated using fixed and random effects models, respectively, according to the heterogeneity among studies. A summary receiver operating characteristics (sROC) curve was constructed and the area under the sROC curve (AUC) was calculated. To explore heterogeneity, due to sources other than threshold effects, I-square was calculated. Results: The present study included analyses of patients (n = 513) from 7 studies. Results indicated a significant heterogeneity for sensitivity and specificity (I 2 9 50% and P G 0.05). The overall pooled estimates for sensitivity and specificity of FDG PET or PET/CT scans in the detection of peritoneal carcinomatosis were 72.4% (95% CI, 64.4%Y79.5%) and 96.7% (95% CI, 94.4%Y98.3%), respectively. The positive likelihood ratio was 10.414 (95% CI, 6.195Y17.506) and the negative likelihood ratio 0.312 (95% CI, 0.159Y0.612). The AUC was 0.9404. The overall diagnostic accuracy (Q* index) was 87.8%. Conclusion: The high specificity may provide the reliability of a positive FDG PET or PET/CT to detect peritoneal carcinomatosis in patients with cancer. FDG PET or PET/CT has only weak power to exclude the presence of peritoneal carcinomatosis. By a good overall diagnostic accuracy, FDG PET or PET/CT may prove beneficial to surgeons when selecting appropriate patients on whom to perform laparoscopy or laparotomy.
trointestinal and gynecological malignancies, principally colorectal carcinoma in men and ovarian cancer in women, as well as primary gastric, pancreatic, adrenocortical carcinoma, breast and lung carcinoma, and mesothelioma. In general, the diagnosis of peritoneal metastatic spread is one of the most important prognostic parameters for the further course of disease. 1, 2 Furthermore, recently introduced oncological interventions, such cytoreductive surgery and/or perioperative intraperitoneal chemotherapy, require prior knowledge of the presence of recurrent or metastatic intraperitoneal lesions. 3, 4 The gold standard is histological verification via laparoscopy or laparotomy. Although a greater number of diagnostic biopsies may be performed with open laparotomy and the ascetic fluid easily sampled, these invasive techniques increase the risk of immediate and delayed complications, and also the time and cost of diagnosis. If a noninvasive imaging technique could identify peritoneal carcinomatosis, this might prevent unnecessary laparoscopy or laparotomy and limit the extent of surgery. Therefore, development of a noninvasive modality which can obtain knowledge on PC would facilitate surgical decision-making and selection of appropriate therapeutic strategies. 5 Positron emission tomography with or without computed tomography (PET or PET/CT) using the radiolabeled glucose analogue 18 F-FDG exploits metabolic characteristic of malignant tissue to identify tumor foci and is a rapidly developing noninvasive technique for various metabolically active cancers. Because of high accuracy for the detection of distant metastasis from various cancers, FDG PET and FDG PET/CT are being increasingly evaluated and applied in the staging and detection of recurrence. 6Y8 Despite the increasing numbers of publications concerning FDG PET or PET/CT in the diagnosis of PC, 9 the quality of current evidences and diagnostic value of FDG PET or PET/CT for PC have yet to be systemically evaluated. Considering this background, the present study conducted a systematic review to assess the diagnostic accuracy of FDG PET or PET/CT in the detection of PC and to provide better evidence-based advice to physicians in this area.
PATIENTS AND METHODS

Literature Search
Abstracts of articles involving human subjects were identified in a comprehensive electronic literature search on MEDLINE and PubMed databases from January 1998 to September 2012, using the following keywords: ''peritoneal carcinomatosis'', ''PET or positron emission tomography or FDG or fluorodeoxyglucose'', and ''sensitivity or specificity or false negative or false positive or diagnosis or detection or accuracy.'' The references reported in all retrieved articles were also extensively checked.
To be eligible for the systemic review, a study had to fulfill the following criteria: (1) they evaluated the use of FDG PET or PET/CT in the detection of peritoneal metastasis in patients with any cancer type and any stage, (2) PET studies using 18 F-FDG as tracer and performed on a dedicated device (excluding gamma camera), (3) sufficient data to (re)construct a 2 Â 2 contingency table to assess the diagnostic accuracy of FDG PET or PET/CT scan, (4) patient-based analysis, (5) histopathological diagnosis was used as the reference standard, (6) including at least 10 patients, and (7) to have been published as a peer reviewed article in the English language. Reports using all modalities of care were included.
Selection of Studies
Two physicians (MCC and CHK) and 1 biostatistician (JHC) reviewed each publication independently to assess their methodological quality, to determine their eligibility for inclusion in the quantitative meta-analysis, and to extract the most important information regarding clinical and PET characteristics. From the studies finally selected, data on (1) first author, (2) year of publication, (3) number of patients analyzed, (4) study design (prospective or retrospective), (5) age distribution of study population, (6) type of tumor, (7) reference standard tests, (8) PET technical characteristics and type of scanner, and (9) totals of true positives, false positives, true negatives, and false negatives were extracted and recorded. Any differences were resolved by consensus. Reviewers were not blinded with regard to information about the journal name, the authors, the author's affiliation, or year of publication since this has been shown to be unnecessary. 10 
Methodological Quality Assessment
The reviewers independently assessed the methodological quality of the selected studies. We assessed the methodological quality of the studies using the quality assessment for studies of diagnostic accuracy (QUADAS) tool. 11 It is the first systematically developed evidence-based quality assessment tool to be used in systematic review of diagnostic accuracy studies. Fourteen methodological quality items were assessed for each study using the scores ''yes,'', ''no,'' or ''unclear'' for each item. ''no'' and ''unclear'' responses were interpreted as having not achieved the quality item. Disagreements between the 2 authors were discussed and resolved by consensus. A quality score for each study was expressed as a percentage of the maximum score of 14. The 14 methodological quality criteria items are specified in Table 1 . A higher quality score indicates a more valid study.
Statistical Analysis
The estimation of sensitivity and specificity are the weighted average by sample size. The degree of heterogeneity among different studies was measured by the Cochran chi-square statistic and I 2 index. If the P value from Cochran chi-square statistic was smaller than 0.05 (significance level) or I 2 greater than 50%, we would detect heterogeneity among studies. In presence of heterogeneity, we would pool the positive/negative likelihood ratio by random-effect model. In absence of heterogeneity, we would apply the fixed effects model. In addition, we also show the sROC curve and Q* index. Q* index is defined by the point closest to the top-left corner of the sROC curve, where sensitivity and specificity are equal. 12, 13 The sROC curve was transformed from the simple linear regression which as the function of sensitivity and specificity. The slope of simple linear regression was often referred to as threshold effect. If the slope was not significant, there was the same diagnostic odds ratio between studies or the diagnostic odds ratio did not vary with different study. In our case, there is no threshold effect. All analyses were performed using MetaDiSc, version 1.4. 14
RESULTS
Study Selection and Characteristics Analysis
Our research initially yielded 166 articles ( Fig. 1 ). Of these, 121 articles were excluded for irrelevant topic after reviewing the title and abstract. Review of the full article excluded further 38 articles. These included 13 case reports, 1 editorial, 6 narrative reviews, 3 animal studies, 2 other diagnostic methods, 2 treatment studies, 2 studies with sample size less than 10 patients, 8 studies performed regionbased analysis, and 1 study not published in English language. We excluded the 8 studies performing regional-based analysis because among 5 studies the definition of peritoneal regions was different, and the other 3 studies had insufficient data to construct a 2 Â 2 table. Finally, a total of 7 articles fulfilled all of the inclusion criteria and were considered for inclusion in the analysis ( Table 2 ). 15Y21 Study Characteristics Table 2 summarizes the 7 studies included in this review. These studies assessed a total of 513 patients. All studies were retrospectively designed. Two studies evaluated patients with gastric cancer and the other 5 studies investigated patients with various types of cancers respectively in the ovary, small bowel, colorectum, endometrium, uterine cervix, pancreas, bile duct, esophagus, stomach, liver, mesothelium, and cancer of primary unknown. Two studies evaluated patients with PET alone and remaining 5 studies with PET/CT. Four studies applied results of histopathology and cytology as confirmative reference, and 3 studies proved PC by histopathology and radiological imaging follow-up. The median prevalence of PC was 50.0% (range 7.9%Y82.1%). Table 1 showed generally moderate quality scores of the included studies with a median score of 64% (range, 50%Y71%). The studies by Lim et al and Berthlot et al 15, 18 obtained the highest quality score. All studies had proper spectrum of patients who had cancers potentially causing PC (item 1); however, in 2 studies the selection criteria were not clearly reported (item 2). All studies had replicable reference standard to classify the status of PC (item 3) and the whole patients in all studies received verification using reference standard (item 5). Five studies had time period short enough (ranges from 1 week to 3 months) between reference standard and FDG PET or PET/CT scan, another study had longer follow-up period that ranged from 3.6 to 46.2 months which may cause disease progression bias, and 1 study provided insufficient time information (item 4). Three studies had a suboptimal design in regard to the examination with the same reference standard because histopathology was examined in part of patients to confirm the diagnosis of suspicious lesions, while other patients were proved by radiological findings or imaging follow-up (item 6). In addition, the imaging follow-up included FDG PET/CT, leading to dependence of reference standard on index result (item 7). All studies described FDG PET or PET/CT technique in detail (item 8); however, in 2 studies the reference standards was insufficiently described to replicate (item 9). Despite retrospective design, in all studies FDG PET or PET/CT scan was always performed first then histopathology or imaging follow-up, thus reasonably the interpretation of FDG PET or PET/CT scan was without knowledge of the results of reference standard (item 10). In contrast, none of the studies mentioned the blindness of interpretation of standard reference (item 11). Two studies offered clinical data when FDG PET or PET/CT was interpreted as in practice, while 5 studies were kept blind or with insufficient information (item 12).
Quality Assessment
None of the enrolled studies mentioned uninterpretable or intermediate FDG PET or PET/CT findings (item 13). Two studies explained reasons for patients' withdrawal (item 14). Table 3 summarizes findings for sensitivity, specificity, positive (LR+) and negative (LRj) likelihood ratios, P values for heterogeneity, and I 2 values. Figure 2 shows the forest plot of sensitivity and specificity, and Figure 3 reveals the positive and negative likelihood ratios of FDG PET or PET/CT for detection of PC. Sensitivity, specificity, and negative likelihood ratio demonstrated significant heterogeneity (I 2 9 50% and P G 0.05), but the positive likelihood ratio showed absence of heterogeneity (I 2 = 34.8% and P 9 0.05). The overall pooled estimates of sensitivity and specificity with 95% confidence interval (CI) FDG PET or PET/CT scan in the detection of PC were 72.4% (95% CI, 64.4%Y79.5%) and 96.7% (95% CI, 94.4%Y98.3%), respectively. The LR+ was 10.414 (95% CI, 6.195Y17.506) and the LRj 0.312 (95% CI, 0.159Y0.612). By the considerably high specificity and high positive likelihood ratio, positive FDG-PET or PET/CT findings should have substantial power to confirm the presence of PC. The negative likelihood ratios translated to a minor expectation to provide a shift in prior probability for negative FDG-PET or PET/CT examination.
Meta-Analysis
The sROC plot presents a global summary of test performance and shows the tradeoff between sensitivity and specificity. Each data point in the sROC plot represents a separate study. Figure 4 shows sROC curves and the Q* index of FDG PET/CT or PET/CT for detection of PC. The AUC was 0.9404. The overall diagnostic accuracy (Q* index) was 87.8%, suggesting an outstanding performance ( Fig. 4 ).
DISCUSSION
Metastatic neoplasm disseminates throughout the peritoneum in four ways: (1) direct spread along the peritoneal ligaments, mesentery, and omentum; (2) seeding through the ascites; (3) lymphatic extension; and (4) embolic hematogenous spread. Frequent sites were omentum, the regions around spleen and liver as well as the small pelvis. 22, 23 Fluid in the right infracolic space flows down the small bowel mesentery to the confluence of the mesentery with the colon. Fluid flow in the left infracolic spaces is often stopped by the sigmoid mesocolon before it flows into the pelvis. 24 Most of the lesions presented themselves as multiple nodular swelling and plaques as diffuse infiltrations into the paracolic fat tissue. In reports describing the characteristics of FDG images, peritoneal metastasis may reveal abnormally intense focal, circumscribed spots of uptake or diffusely uniform FDG uptake corresponding to nodular and diffuse peritoneal disease, 16, 25 and nodular or curvilinear uptake along the liver surface. 20 On sagittal sections, a vertical straight line may be seen demarcating the boundary between diffusely increased activity in the peritoneum and low activity in the retroperitoneum. 26 The present meta-analysis including data from 513 patients with various types of cancer showed that FDG PET or PET/CT had a good positive likelihood ratio (10.414) suggesting FDG PET or PET/CT may prove useful in confirming PC. A positive FDG-PET or PET/CT scan could increase the probability of PC by about 45%. 27 In addition, because of its high specificity, FDG PET or PET/CT could play a role in the equivocal cases as this precludes missing the chance for performing curative surgery. However, our meta-analysis study demonstrated a limited sensitivity for detection of PC with 18 F-FDG PET or PET/CT (72.4%) and just a useful value of negative likelihood ratio (0.312). These values suggests that a negative result of FDG PET or PET/CT had only weak power to exclude PC and could not be used alone as a justification. The only adequate tool in the initial staging remains explorative surgery with histopathological evaluation of the obtained biopsies.
Several possible reasons may explain the compromised moderate sensitivity of 18 F-FDG PET or PET/CT. First, only lesions with sufficient malignant cells to change the glucose metabolism can be detected. Two enrolled articles specifically studying gastric cancer had much lower sensitivities compared with those studying other various types of tumors. A systemic review by Wang and Chen et al 28 provided an overview of diagnostic performance of multiple modalities in detecting hepatic and peritoneal metastasis of gastric cancer. In the part of 18 F-FDG PET in detecting PC, they meta-analyzed 4 PET-only studies compared to our 2 studies utilizing PET and PET/CT, respectively, however, with similar total number of patients. The results of low pooling sensitivity of 28% and high pooling specificity of 97% were in line with our results in detecting PC of gastric cancer. Mucinous and signet ring cell carcinomas tend to show significantly lower 18 F-FDG uptake than did the other histological types of gastric cancer, 29, 30 probably because of the low concentration of cancer cells with a lot of stromal tissue, in spite of their aggressiveness. Besides, the differentiation of primary and metastatic cancer lesions can be very different. The second potential reason for the moderate sensitivity is the limited spatial resolution of the PET component in the range of 0.4-0.6 cm, which is usually larger than the size of peritoneal micro-metastasis. Therefore, FDG PET or PET/CT may be limited to detect small seeded peritoneal nodules. 31Y33 Third, 18 F-FDG is a nonspecific tracer with the resultant many chances of increased uptake, like the physiological increased glucose turnover in the bowel. The lesions located close to bowel loops and diffuse in their configuration may be wrongly considered or misregistrated to be physiological intestinal uptake and thus show false-negative findings at FDG PET or PET/CT. Finally, FDG-PET imaging cannot detect ascetic fluid, which was the most common finding of PC; however, this could easily be detected with PET/CT. Diagnostic CT is usually the first imaging modality for detecting PC, however, with widely different sensitivity ranging from 24% to 91%. 34Y36 The sensitivity of diagnostic CT depends on factors such as the size, site, and morphology of tumor deposits; the presence of ascites; the paucity of intra-abdominal fat; the adequacy of bowel opacification; and the concomitant use of peritoneography. Three of our enrolled studies showed a better diagnostic performance of FDG-PET or PET/CT scan than diagnostic CT scan in the detection of peritoneal carcinomatosis 17,20,21 and 2 studies had comparable results. 16, 18 Magnetic resonance with diffusion-weighted imaging (MR-DWI), another new functional imaging reflecting tumoral cellularity, have been studied in assessing PC staging. 37 Two enrolled studies revealed that FDG PET/CT and MR-DWI both were accurate in the identification of patients with PC, and MR-DWI appeared more sensitive than PET/CT in the detection of supramesocolic lesions. 19, 21 Further study with head-to-head comparison among these imaging modalities in the detection of PC is suggested.
Our study had several limitations. First, considering the various types of cancer in our enrolled articles, the number of enrolled studies and the number of patients with every specified cancer were small and limited. Further studies with a larger sample size are needed to statistically confirm our results. The exclusion of conference abstracts, letters to the editors, and nonYEnglish-language studies may have led to publication bias, which can be tested by funnel plots. In this metaanalysis, funnel plot analysis was not performed because the limited number of enrolled studies could have decreased the power for detection of publication bias. The second was the retrospective nature in all enrolled studies, which could cause selection bias. Third, the diagnosis of PC was not always evaluated histopathologically, which may have affected the evaluation of FDG-PET or PET/CT scan. There was the possibility of including cases in which false-positive lesions were considered as true-positive lesions by imaging follow-up. Meta-analysis often fails to account for verification or work-up difference between studies. Fourth, we enrolled studies analyzing on a per-patient basis, rather than the site-by-site correlation of FDG PET or PET/CT and the surgical or imaging findings. We believed that the diagnosis of peritoneal spread is a more critical observation. In addition, the ways to divide the peritoneum differed among studies, and it was not reasonable to compare those site-by-site data. Fifth, the presence of clinical heterogeneity (heterogeneity originated by the inclusion of patients with various cancers, different imaging methodologies, and the manners of reference test) influence the generalizability of the results of FDG PET or PET/CT. Finally, the current study was unable to identify if FDG PET/CT is better than FDG PET alone. The present study also did not compare FDG PET or PET/CT with other imaging modalities such as MRI or diagnostic CT scan because systematic deviation exists among modalities using different imaging mechanisms, and the number studies of head-to-head comparison was limited.
